GRI · GRI Bio Inc. Common Stock
View on chartInsiders & Stakes
| Hertz Walter Marc Chief Executive Officer | ▲ Buy | Grant | 385,510 Shares held | 4/21/2023 | View profile |
| Agro Albert Chief Medical Officer | ▲ Buy | Grant | 172,189 Shares held | 4/21/2023 | View profile |
| Chaturvedi Vipin Chief Scientific Officer | ▲ Buy | Grant | 172,189 Shares held | 4/21/2023 | View profile |
| Thorell Marella Director | ▼ Sell | Other | 9,506 Shares held | 12/13/2022 | View profile |
Transaction History
| Hertz Walter Marc | ▲ Buy | Grant | 385,510 | — | 4/21/2023 |
| Agro Albert | ▲ Buy | Grant | 172,189 | — | 4/21/2023 |
| Chaturvedi Vipin | ▲ Buy | Grant | 172,189 | — | 4/21/2023 |
| Thorell Marella | ▼ Sell | Other | 28,517 | $0 | 12/13/2022 |
| Thorell Marella | ▲ Buy | Grant | 38,023 | $0 | 7/1/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GRI Bio to Present IPF Data at 10th IPF Summit
GRI Bio announced it will present insights on immune modulation and Phase 2a development for idiopathic pulmonary fibrosis (IPF) at the 10th IPF Summit. This upcoming event provides a key update on the company's clinical progress. The stock is currently trading well below its 52-week high, with analysts maintaining a wide range of price targets.
GRI Bio to Present IPF Data at 10th IPF Summit. GRI Bio announced it will present insights on immune modulation and Phase 2a development for idiopathic pulmonary fibrosis (IPF) at the 10th IPF Summit. This upcoming event provides a key update on the company's clinical progress. The stock is currently trading well below its 52-week high, with analysts maintaining a wide range of price targets.